Biodel Inc. to Report Third Quarter Fiscal Year 2010 Financial Results on August 5, 2010

DANBURY, Conn., July 30 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) will issue its third quarter fiscal year 2010 financial results on August 5, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

August 5, 2010 schedule:

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

The Trout Group LLC

Seth D. Lewis, +1-646-378-2952

SOURCE Biodel Inc.